Salesforce
CRM
Oracle
ORCL
Tesla
TSLA
4
Microsoft
MSFT
5
Coinbase
COIN
US Stock MarketDetailed Quotes
EXOZ eXoZymes
- 13.090
- -0.440-3.25%
Trading Apr 24 09:54 ET
109.53MMarket Cap-14.71P/E (TTM)
14.000High12.430Low7.95KVolume13.530Open13.530Pre Close106.56KTurnover0.13%Turnover RatioLossP/E (Static)8.37MShares23.99052wk High10.51P/B82.09MFloat Cap8.50052wk Low--Dividend TTM6.27MShs Float23.990Historical High--Div YieldTTM11.60%Amplitude8.500Historical Low13.404Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
eXoZymes Stock Forum
Game-Changing BioClick Platform Secures NIH Grant for Next-Gen Drug Development
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
Thursday, 10th April at 4:30 pm
Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate ...
No comment yet